MX2009010729A - Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida. - Google Patents

Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.

Info

Publication number
MX2009010729A
MX2009010729A MX2009010729A MX2009010729A MX2009010729A MX 2009010729 A MX2009010729 A MX 2009010729A MX 2009010729 A MX2009010729 A MX 2009010729A MX 2009010729 A MX2009010729 A MX 2009010729A MX 2009010729 A MX2009010729 A MX 2009010729A
Authority
MX
Mexico
Prior art keywords
diazepin
benzo
dihydro
sulfonamide derivatives
formula
Prior art date
Application number
MX2009010729A
Other languages
English (en)
Inventor
Thomas Johannes Woltering
Juergen Wichmann
Silvia Gatti Mcarthur
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009010729A publication Critical patent/MX2009010729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I), a un proceso para la obtención de los mismos, a su utilización para la fabricación de medicamentos destinados a tratar trastornos del SNC y a composiciones farmacéuticas que los contienen. Los compuestos de la fórmula (I) se representan mediante la fórmula general (I) en donde R1, R2, R3 y R4 tienen los significados definidos en la descripción.
MX2009010729A 2007-04-19 2008-04-09 Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida. MX2009010729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106522 2007-04-19
PCT/EP2008/054257 WO2008128889A1 (en) 2007-04-19 2008-04-09 Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives

Publications (1)

Publication Number Publication Date
MX2009010729A true MX2009010729A (es) 2009-10-26

Family

ID=39532268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010729A MX2009010729A (es) 2007-04-19 2008-04-09 Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.

Country Status (17)

Country Link
US (1) US7511033B2 (es)
EP (1) EP2137167B1 (es)
JP (1) JP2010524879A (es)
KR (1) KR101151993B1 (es)
CN (1) CN101657432B (es)
AR (1) AR066086A1 (es)
AT (1) ATE519751T1 (es)
AU (1) AU2008240802B2 (es)
BR (1) BRPI0810655A2 (es)
CA (1) CA2684760A1 (es)
CL (1) CL2008001083A1 (es)
ES (1) ES2369866T3 (es)
IL (1) IL201198A0 (es)
MX (1) MX2009010729A (es)
PE (1) PE20090148A1 (es)
TW (1) TW200904448A (es)
WO (1) WO2008128889A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
WO2013033246A2 (en) 2011-08-29 2013-03-07 Braincells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
KR20160080799A (ko) 2014-12-30 2016-07-08 한국해양과학기술원 금 촉매를 이용한 α-피론 유도체 전합성 방법 및 이에 의해 합성되어 인간 암세포주에 세포독성을 가지는 α-피론 유도체
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032775A (ja) 1983-07-30 1985-02-19 Daikin Ind Ltd 含フッ素ベンゾジアゼピン類
GB8601004D0 (en) 1986-01-16 1986-02-19 Fujisawa Pharmaceutical Co 1,5-benzodiazepine derivatives
GB9018601D0 (en) 1990-08-24 1990-10-10 Fujisawa Pharmaceutical Co Tricyclic compounds
CA2054455A1 (en) 1990-11-23 1992-05-24 John James Delany Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides
US5618812A (en) 1992-07-29 1997-04-08 Merck Sharp & Dohme, Ltd. Benzodiazepine derivatives
GB9314981D0 (en) 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
EP0843660A1 (en) 1995-07-31 1998-05-27 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
NZ315677A (en) 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
AU6420700A (en) 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
KR100481386B1 (ko) 1999-10-15 2005-04-08 에프. 호프만-라 로슈 아게 벤조디아제핀 유도체
CN1195522C (zh) * 1999-10-15 2005-04-06 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
DK1379511T3 (da) 2001-04-12 2005-11-07 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
DE60202761T2 (de) 2001-04-12 2006-01-12 F. Hoffmann-La Roche Ag Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
CN101657432A (zh) 2010-02-24
BRPI0810655A2 (pt) 2014-11-04
ES2369866T3 (es) 2011-12-07
EP2137167B1 (en) 2011-08-10
AU2008240802A1 (en) 2008-10-30
CL2008001083A1 (es) 2008-10-24
PE20090148A1 (es) 2009-02-26
KR20100005715A (ko) 2010-01-15
KR101151993B1 (ko) 2012-06-01
EP2137167A1 (en) 2009-12-30
CN101657432B (zh) 2013-04-10
WO2008128889A1 (en) 2008-10-30
US20080261957A1 (en) 2008-10-23
AU2008240802B2 (en) 2012-07-05
ATE519751T1 (de) 2011-08-15
TW200904448A (en) 2009-02-01
AR066086A1 (es) 2009-07-22
JP2010524879A (ja) 2010-07-22
IL201198A0 (en) 2010-05-17
CA2684760A1 (en) 2008-10-30
US7511033B2 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
TW200716121A (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
TW200740789A (en) Pyridine and pyrimidine derivatives as mGluR2 antagonists
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
ATE523514T1 (de) Tricyclische triazolische verbindungen
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200833670A (en) Novel compounds 569
GB0313612D0 (en) Organic compounds
TW200639156A (en) New compounds
JO2673B1 (en) Diosmetin compounds, method of preparation and pharmaceutical compositions
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MY146802A (en) Novel drugs for treating respiratory diseases
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
MX2009005544A (es) Indoles.
MX2009010729A (es) Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.

Legal Events

Date Code Title Description
FG Grant or registration